Prognostic significance of neuroendocrine differentiation in prostate cancer

被引：17
|
作者：
Ather, MH [1 ]
Abbas, F [1 ]
机构：
[1] Aga Khan Univ Hosp, Dept Surg, Urol Sect, Karachi, Pakistan
来源：
EUROPEAN UROLOGY | 2000年 / 38卷 / 05期
关键词：
neuroendocrine differentiation; prostate cancer; small cell carcinoma; androgen receptor; hormone refractory prostate cancer;
D O I：
10.1159/000020352
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：535 / 542
页数：8
相关论文
共 50 条
  • [31] The spectrum of neuroendocrine differentiation in prostate cancer
    Cheng, Siyuan
    Yu, Xiuping
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1214 - 1215
  • [32] Neuroendocrine differentiation in prostate cancer and development
    Sanders, Danielle N.
    Grabowska, Magdalena
    Matusik, Robert
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (03)
  • [33] The spectrum of neuroendocrine differentiation in prostate cancer
    Siyuan Cheng
    Xiuping Yu
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1214 - 1215
  • [34] Neuroendocrine differentiation of prostate cancer: a review
    Parimi, Vamsi
    Goyal, Rajen
    Poropatich, Kate
    Yang, Ximing J.
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2014, 2 (04): : 273 - 285
  • [35] Neuroendocrine differentiation in the precursors of prostate cancer
    diSantAgnese, PA
    EUROPEAN UROLOGY, 1996, 30 (02) : 185 - 190
  • [36] Prognostic role of neuroendocrine differentiation marker in prostate adenocarcinoma
    Zhu, Menglei
    Chen, Wei
    Glover, Michael
    Shankar, Eswar
    MacLennan, Gregory T.
    Gupta, Sanjay
    CANCER RESEARCH, 2017, 77
  • [37] Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer
    S. S. Jeetle
    G. Fisher
    Z. H. Yang
    E. Stankiewicz
    H. Møller
    C. S. Cooper
    J. Cuzick
    D. M. Berney
    Virchows Archiv, 2012, 461 : 103 - 107
  • [38] Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer
    Jeetle, S. S.
    Fisher, G.
    Yang, Z. H.
    Stankiewicz, E.
    Moller, H.
    Cooper, C. S.
    Cuzick, J.
    Berney, D. M.
    VIRCHOWS ARCHIV, 2012, 461 (02) : 103 - 107
  • [39] Neuroendocrine differentiation of prostate cancer and clinical outcome of Everolimus against neuroendocrine prostate cancer (NEPC)
    Shimomura, Tatsuya
    Kurauti, Takashi
    Sakanaka, Keigo
    Suzuki, Hidenori
    Goto, Hirokazu
    Endo, Yasuhiko
    Egawa, Shin
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 : 359 - 359
  • [40] Neuroendocrine differentiation in colorectal carcinomas assessing its prognostic significance
    Atasoy, P
    Ensari, A
    Demirci, S
    Kursun, N
    TUMORI, 2003, 89 (01) : 49 - 53
12345